Hyattsville, Maryland Clinical Trials

A listing of Hyattsville, Maryland clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 134 clinical trials
Diagnosis of Pheochromocytoma

The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe …

adrenaline
positron emission tomography
myocardial infarction
somatostatin
chromogranin a
National Institutes of Health Clinical Center, 9000 Rockville Pike
 (9.7 away) Contact site
  • 16 views
  • 27 Dec, 2020
  • +1 other locations
A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

This is a Phase I, open-label, dose escalation and dose expansion study with BID (suspension) and TID (tablet) oral dose of tazemetostat. Subjects will be screened for eligibility within 14 days of the planned first dose of tazemetostat. A treatment cycle will be 28 days. Response assessment will be evaluated …

Children's National Medical Center
 (5.4 away) Contact site
  • 0 views
  • 17 Jan, 2021
  • +35 other locations
Study of TSR-042 an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody in Participants With Advanced Solid Tumors

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics …

solid neoplasm
endocrine therapy
advanced malignant solid tumor
solid tumor
measurable disease
GSK Investigational Site
 (7.8 away) Contact site
  • 0 views
  • 17 Jun, 2020
  • +186 other locations
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are …

bone marrow procedure
measurable disease
pd-l1
lymphoma
Lombardi Comprehensive Cancer Center - MedStar Georgetown University Hospital
 (7.9 away) Contact site
  • 392 views
  • 08 May, 2020
  • +40 other locations
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging …

metastasis
breast cancer
MRI
trastuzumab
cancer
Georgetown University Medical Center
 (7.9 away) Contact site
  • 79 views
  • 22 Oct, 2020
  • +25 other locations
A Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in HIV-1 infected participants undergoing ART interruption.

antiretroviral agents
antiretroviral therapy
immunodeficiency
HIV Vaccine
antiretroviral
George Washington University Medical Faculty Associates /ID# 213893
 (7.0 away) Contact site
  • 147 views
  • 21 Dec, 2020
  • +25 other locations
First-in-human Study of BAY2287411 Injection a Thorium-227 Labeled Antibody-chelator Conjugate in Patients With Tumors Known to Express Mesothelin

The purpose of this study is to evaluate, in patients with tumors known to express the protein mesothelin, the following properties of BAY2287411 injection: safety (to identify, assess, minimize, and appropriately manage the risks associated to the study drug) tolerability (the degree to which side effects can be tolerated by …

National Cancer Institute
 (9.7 away) Contact site
  • 266 views
  • 09 Jan, 2021
  • +9 other locations
A Study Exploring the Safety Tolerability Pharmacokinetics and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and early clinical activity of INCB086550 in participants with advanced solid tumors who have failed prior treatments.

solid tumor
monoclonal antibodies
Medstar Georgetown Medical Center, Inc
 (7.8 away) Contact site
  • 0 views
  • 12 Nov, 2020
  • +27 other locations
Walking Therapy In Hemiparetic Stroke Patients Using Robotic-Assisted Treadmill Training

The overall goal of this study is to determine whether robotic-assisted gait training is better than standard physical therapy treatments for improving walking ability in hemiparetic stroke patients.

stroke
gait training
hemiparesis
other therapy
National Rehabilitation Hospital
 (5.4 away) Contact site
  • 19 views
  • 07 Nov, 2020
  • 1 location
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

This is a multicenter, open-label, first-in-human Phase 1 study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts: with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose …

solid neoplasm
immunostimulants
solid tumor
carboplatin
fluoropyrimidine
GSK Investigational Site
 (7.8 away) Contact site
  • 0 views
  • 03 Dec, 2020
  • +119 other locations